2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 106

Rheumatology Fellows Teaching in a Consult Setting: Pilot Project at Two Training Hospitals
Abstract Number: 101

Rime (Reporter-Interpreter-Moderator-Educator) Evaluation Tool to Assess Fellows in Rheumatology
Abstract Number: 1279

Risk Factors for Achieving a Drug-Free Remission in Patients with Juvenile Dermatomyositis
Abstract Number: 2309

Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Abstract Number: 317

Risk Factors for Blood Transfusions Following Total Joint Arthroplasty in Patients with Rheumatoid Arthritis
Abstract Number: 1268

Risk Factors for Bone Loss in Juvenile-Onset Systemic Lupus Erythematosus: A Prospective Study
Abstract Number: 1618

Risk Factors for Development of Early Infectious and Non-Infectious Complications in Systemic Lupus Erythematosus Patients Undergoing Major Surgery
Abstract Number: 1961

Risk Factors for Low Muscle MASS in Community-Dwelling Older Women: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health Study
Abstract Number: 717

Risk Factors for Neuropsychiatric Systemic Lupus Erythematosus and Its Recurrence
Abstract Number: 1750

Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study
Abstract Number: 2844

Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
Abstract Number: 1113

Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study
Abstract Number: 1691

Risk of Development of Definite Disease in Patients with Early Systemic Sclerosis
Abstract Number: 2188

Risk of Disability in Underweight Persons with or at Increased Risk of Knee Osteoarthritis
Abstract Number: 1035

Risk of Hospitalization Among RA Patients with Multiple Autoimmune Co-Morbidities Differs By DMARD Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].